Hepatitis after gene therapy, what are the possible causes?

Area of Science:

• Hepatology
• Gene Therapy
• Immunology

Background:

• Gene therapy for hemophilia using adeno-associated virus (AAV) vectors shows promise in increasing clotting factor levels.
• Hepatitis, indicated by elevated alanine aminotransferases (ALT), is a frequent adverse event in these trials.
• The clinical significance of this transient, often asymptomatic liver injury remains unclear.

Purpose of the Study:

• To investigate the causes and implications of hepatitis following gene therapy for hemophilia.
• To understand the mechanisms behind transgene expression loss and liver injury.
• To assess the overall safety profile and optimize future gene therapy strategies.

Main Methods:

• Review of clinical trial data and liver biopsy findings.
• Analysis of hepatocellular injury markers (ALT).
• Evaluation of potential etiological factors including immune responses and direct viral toxicity.

Main Results:

• Hepatitis is common but typically transient and asymptomatic, not meeting Hy's Law criteria for drug-induced liver injury (DILI).
• Liver biopsies show sinusoidal infiltration without significant inflammation years post-therapy.
• Potential causes include T-cell responses to AAV vectors, direct viral capsid injury, or unfolded protein response.

Conclusions:

• Gene therapy for hemophilia has a favorable safety profile despite common transaminitis.
• Pre-therapy monitoring with liver function tests and fibroscans is recommended.
• Further research into the mechanisms of liver injury and transgene loss is crucial for optimizing hemophilia gene therapy.